Last updated: March 2, 2026
What is the drug associated with NDC 70000-0720?
NDC 70000-0720 corresponds to Ozempic (semaglutide), a GLP-1 receptor agonist used to improve glycemic control in adults with type 2 diabetes and to reduce major cardiovascular events in high-risk patients.
What is the current market landscape for Ozempic?
Market Size and Penetration
- Global Market Value: Estimated at $7.5 billion in 2022.
- US Market Share: Accounts for approximately 60% of global sales.
- Prescription Volume: Over 5 million prescriptions filled annually in the US.
- Competitors: Includes Wegovy (semaglutide for weight management), Trulicity (dulaglutide), and Victoza (liraglutide).
Key Drivers
- Rising prevalence of type 2 diabetes.
- Increasing approval for weight management indications.
- Expanded payer coverage.
- Demonstrated efficacy in cardiovascular risk reduction.
Limitations
- High drug acquisition cost.
- Reimbursement and access barriers.
- Competition from biosimilars projected after patent expiration.
What are current pricing strategies?
Launch Pricing and Current Prices
- US Wholesale Acquisition Cost (WAC): Approximately $935 per 4-week pen.
| Formulation |
Price (WAC) |
Dosing Schedule |
Approximate Annual Cost |
| Ozempic (0.5 mg) |
$935 |
Once weekly |
$4,700 |
| Ozempic (1 mg) |
$935 |
Once weekly |
$4,700 |
Reimbursement Trends
- Most insurers cover Ozempic with prior authorization.
- Copays vary, with many patients paying between $25 to $50 per month after copay assistance.
Price Trends
- Historically, prices for Ozempic have increased annually by 4-6%.
- Market pressure from biosimilars and generic competitors could influence price reduction strategies within 3-5 years.
What are projected market developments?
Regulatory and Patent Status
- Patent Expiration: Expected around 2027-2028.
- Biosimilar Entry: Anticipated from 2028 onward, potentially reducing prices by 20-40%.
Market Growth Projections
- Compound annual growth rate (CAGR) expected at 8-10% until 2030.
- Uptake driven by expanding indications and patient acceptance.
Forecasted Pricing
| Year |
Estimated Average Wholesale Price (AWP) |
Notes |
| 2023 |
$935 per 4-week pen |
Current level |
| 2025 |
$895 |
Slight decrease assumed due to market competition |
| 2028 |
$700 |
Post-patent expiration and biosimilar entry |
| 2030 |
$650 |
Further price reductions expected |
Note: These are estimates based on current trends and anticipated market dynamics; actual prices may vary depending on healthcare policy, manufacturer strategies, and biosimilar development.
What are the key factors influencing future price projections?
- Patent cliff in 2027-2028: Biosimilar competition expected to exert downward pressure.
- Market penetration into weight management and cardiovascular uses may sustain higher prices.
- Insurance coverage expansions and negotiations could influence the out-of-pocket cost.
- Manufacturing costs and supply chain stability will impact pricing flexibility.
What is the risk outlook?
- Patent litigation or delays may extend exclusivity and sustain higher prices.
- Regulatory changes could influence pricing strategies or reimbursement policies.
- Market saturation may limit sales growth, pressuring price adjustments.
Key Takeaways
- Ozempic (NDC 70000-0720) is a high-growth GLP-1 receptor agonist with significant market share in type 2 diabetes management.
- Current US wholesale price is approximately $935 per 4-week dose; annual patient costs hover around $4,700.
- Patent expiration around 2027-2028 will likely introduce biosimilars, reducing prices by an estimated 20-40%.
- Revenue growth is driven by expanding indications and increasing prevalence but faces pricing pressures from biosimilar competition and healthcare policy changes.
- Price projection estimates suggest gradual declines post-patent expiry, with retail prices potentially dropping to around $650 per 4-week dose by 2030.
FAQs
Q1: When does patent expiry for Ozempic (semaglutide) occur?
A: Patent protection is expected to expire around 2027-2028.
Q2: How much could biosimilars reduce Ozempic's price?
A: Biosimilar entry could decrease prices by approximately 20-40%.
Q3: What competitors pose a market threat?
A: Trulicity (dulaglutide), Victoza (liraglutide), and emerging biosimilars.
Q4: Are there any pricing differences between indications?
A: Not significantly; the primary driver is market competition and reimbursement policies.
Q5: How is reimbursement evolving?
A: Insurance coverage expands, with many patients paying lower copays via assistance programs, but coverage varies by payer.
References
- IQVIA. (2022). Pharmaceutical market data.
- FDA. (2022). Ozempic (semaglutide) approval and indications.
- Bloomberg Intelligence. (2022). Biosimilar market outlook.
- Centers for Medicare & Medicaid Services. (2022). Drug pricing and reimbursement.
- EvaluatePharma. (2022). Global GLP-1 market forecast.
